Skip to main content
Article thumbnail
Location of Repository

Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State

By Hillel Haim, Zhihai Si, Navid Madani, Liping Wang, Joel R. Courter, Amy Princiotto, Aemro Kassa, Marciella DeGrace, Kathleen McGee-Estrada, Megan Mefford, Dana Gabuzda, Amos B. Smith and Joseph Sodroski

Abstract

Binding to the CD4 receptor induces conformational changes in the human immunodeficiency virus (HIV-1) gp120 exterior envelope glycoprotein. These changes allow gp120 to bind the coreceptor, either CCR5 or CXCR4, and prime the gp41 transmembrane envelope glycoprotein to mediate virus–cell membrane fusion and virus entry. Soluble forms of CD4 (sCD4) and small-molecule CD4 mimics (here exemplified by JRC-II-191) also induce these conformational changes in the HIV-1 envelope glycoproteins, but typically inhibit HIV-1 entry into CD4-expressing cells. To investigate the mechanism of inhibition, we monitored at high temporal resolution inhibitor-induced changes in the conformation and functional competence of the HIV-1 envelope glycoproteins that immediately follow engagement of the soluble CD4 mimics. Both sCD4 and JRC-II-191 efficiently activated the envelope glycoproteins to mediate infection of cells lacking CD4, in a manner dependent on coreceptor affinity and density. This activated state, however, was transient and was followed by spontaneous and apparently irreversible changes of conformation and by loss of functional competence. The longevity of the activated intermediate depended on temperature and the particular HIV-1 strain, but was indistinguishable for sCD4 and JRC-II-191; by contrast, the activated intermediate induced by cell-surface CD4 was relatively long-lived. The inactivating effects of these activation-based inhibitors predominantly affected cell-free virus, whereas virus that was prebound to the target cell surface was mainly activated, infecting the cells even at high concentrations of the CD4 analogue. These results demonstrate the ability of soluble CD4 mimics to inactivate HIV-1 by prematurely triggering active but transient intermediate states of the envelope glycoproteins. This novel strategy for inhibition may be generally applicable to high–potential-energy viral entry machines that are normally activated by receptor binding

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2655723
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2001). 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
    2. (2001). Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4. Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)-butanes.
    3. (2001). Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
    4. (1997). Atomic structure of a thermostable subdomain of HIV-1 gp41.
    5. (1991). Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.
    6. (2002). Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.
    7. (1998). Capture of an early fusionactive conformation of HIV-1 gp41.
    8. (1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
    9. (1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    10. (1993). Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    11. (2004). Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    12. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
    13. (1998). Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.
    14. (1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    15. (1998). Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
    16. (1998). Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
    17. (1991). Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    18. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    19. (1999). Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.
    20. (2000). Energetics of the HIV gp120-CD4 binding reaction.
    21. (1990). Enhancement of SIV infection with soluble receptor molecules.
    22. (2002). Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
    23. (1995). Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    24. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
    25. (2000). Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
    26. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
    27. (2001). Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.
    28. (1990). High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    29. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    30. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
    31. (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    32. (2001). HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Envmediated fusion process.
    33. (1992). Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.
    34. (1998). Human Retroviruses and AIDS. Los Alamos: Los Alamos Natl.
    35. (1996). Identification of a major co-receptor for primary isolates of HIV-1.
    36. (2005). Identification of N-phenyl-N9-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    37. (2007). Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.
    38. (2006). Kinetic dependence to HIV-1 entry inhibition.
    39. (1992). Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
    40. (2001). Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes.
    41. (1996). Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.
    42. (2007). Panet A
    43. (1994). Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
    44. (1993). Quantitation of human immunodeficiency virus type 1 infection kinetics.
    45. (1999). Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes.
    46. (2003). Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.
    47. (1995). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell linepassaged human immunodeficiency virus type 1 isolates.
    48. (2007). Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission.
    49. (2008). Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.
    50. (1991). Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials.
    51. (2007). Structural definition of a conserved neutralization epitope on HIV-1 gp120.
    52. (2005). Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.
    53. (1996). The betachemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
    54. (2001). The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter].
    55. (2006). The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.
    56. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    57. (2001). The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments.
    58. (2006). Thermodynamics of binding of a low–molecular-weight CD4 mimetic to HIV-1 gp120.
    59. (2000). Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection.
    60. (1993). Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    61. (1996). Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes.
    62. (1992). Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.